Sanofi-Aventis opens $2B bid for Zentiva

20 July 2008

Sanofi-Aventis Europe, a division of the French drug major, has opened an offer to acquire all issued ordinary shares, including those held in the form of GDSs, of Czech generics company Zentiva for 40.04 billion koruna ($2.67 billion).

This equates to 1,050 koruna per share, a 14.6 % premium over the April 30 closing price of 916.60 koruna. The previous announcement of the bid (Marketletter June 23) eclipsed an offer of 950 koruna per share by Dutch conglomerate PPF through its subsidiary Anthiarose.

Offer open to September 19

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



More ones to watch >




Today's issue

Company Spotlight